LONDON (Alliance News) - Drugmaker GlaxoSmithKline PLC on Thursday said it has started a phase one clinical trial on GSK3359609, a T-cell costimulator designed to boost the anti-tumour response from the immune system.
The study marks the start of a two-part clinical trial to evaluate the safety and pharmacokinetic properties of the treatment in patients with advanced or recurrent solid tumours.
"We are at a very exciting point in the development of new immuno-oncology agents which have the potential to expand the results seen with checkpoint inhibitors. Novel targets like ICOS will be at the forefront of these new agents and this study will give us the first look at the effects of stimulating the immune system by activating the ICOS receptor," said Axel Hoos, senior vice-president and therapeutic area head of oncology at Glaxo.
Glaxo shares were down 0.5% to 1,551.50 pence.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)